A medical emergency in a gym class started Megann’s life-changing journey with epilepsy, including a sudden diagnosis and intense treatment plan. Discover Megann’s inspiring story, detailing her challenges with treatment, loss of independence and how she empowers herself and other to live life to the fullest.

Jesse was a senior in college studying to become a doctor when he was diagnosed with acute lymphoblastic leukemia (ALL). His studies in the medical field inspired him to ask critical questions and advocate for himself throughout his ALL journey. By combining this determination with a positive attitude, Jesse navigated one of the most challenging times of his life with resilience and hope.

Rachael was just 36 years old when she was diagnosed with breast cancer. Her decade long treatment journey has left its mark and worries for the future, but emerging out of the darkness is a cherished son she wasn’t sure if she could have, a powerful drive to help others on their cancer journeys and true perspective on what matters in life.

Narcolepsy is a chronic, neurologic sleep disorder, and people living with the condition are at increased risk of developing cardiovascular (CV) and cardiometabolic (CM) comorbidities. New expert consensus recommendations provide more clarity on these risks, including obesity, diabetes, dyslipidemia as well as hypertension and offer actionable behavioral, therapeutic, and dietary strategies that aim to holistically mitigate these risks.

HER2 plays an important role in cell growth and survival, but many cancers, including gastroesophageal adenocarcinoma (GEA), can overexpress this protein, leading to uncontrolled cell growth and impacting prognosis. While not everyone diagnosed with a GEA will be HER2-positive, it is helpful to test for HER2 as the presence of this protein can help inform the treatment approach.

Bispecific antibodies are showing potential in the fight against HER2-expressing cancers. This innovative approach is designed to target two specific protein receptors, providing a new and effective way to treat aggressive forms of cancer that overexpress the HER2 protein. With their ability to simultaneously target two different antigens, bispecific antibodies offer a novel approach to treating solid tumors, including the possibility for new first-line treatments. 

Hear from Heidi Manna, Chief People Officer, on how the Jazz Remix flexible working model is designed to provide a greater level of flexibility to how and where work gets done, helping teams pioneer solutions to transform the lives of patients.

Sam Pearce stepped into the newly created position of Jazz Chief Commercial Officer in August 2024, bringing with her an established track record of effectively scaling commercial operations to achieve transformational growth and accelerate patient access to medicines across geographies. One hundred days in, Sam shares her initial experiences and vision for the future of her role and Jazz.

Developmental and Epileptic Encephalopathies (DEEs) are a group of rare and severe epilepsies which are characterized by seizures and significant developmental delays. Most DEEs begin in early life, often in infancy, with children experiencing frequent and severe seizures, which can be of multiple types. This generates a complex clinical picture in which both developmental abnormalities and severe epilepsy contribute to the functional impairment of these children which continues into adulthood.